In June 2025, Fractyl presented preclinical data at the American Diabetes Association’s 85th Scientific Sessions that showed ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...

Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly “bribing” providers to prescribe its ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Texas Attorney General Ken Paxton on Thursday announced a lawsuit alleging that Eli Lilly (NYSE:LLY) bribed his state's medical providers in a bid to persuade them to prescribe the company’s weight ...

Q3 2025 Management View CEO Mitchell S. Steiner reported that Veru is focusing its late clinical-stage biopharmaceutical efforts on cardiometabolic and inflammatory diseases, emphasizing two clinical ...

As lawyers who represent whistleblowers under the False Claims Act, we expect a new era of fraud cases tied to GLP-1 drugs, ...

Discover how GLP-1 medications and the MAHA movement are driving protein consumption and creating new opportunities for ...

The product is viewed by the CPG giant as a “one-of-a-kind opportunity” to help consumers rebuild or maintain muscle they ...

Data suggests that some sectors of Europe's confectionery sector are declining. Could GLP-1s have a role to play in this?

Peptide therapeutics are rapidly emerging as a promising class of interventions for obesity, driven by growing insights into their ability to modulate key ...

Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye ...